- Login
- Manage Portfolio
- Post a StockTalk
- Write an Instablog
- Get Daily Email Alert
-
Seeking Alpha
|
|
| 52wk high: | |
| 52wk low: | |
| EPS: | |
| PE: | |
| Dividend: | |
| Yield: | |
| Market Cap: | |
| Exchange: | |
-
Expect FDA Approval of AMAG Pharmaceutical's Feraheme
-
China Rising: CCG's May 18th Chinese Investment Conference
-
Biotech Opportunities: Look for Decent Pipeline, Big Pharma Partnerships
-
3S Bio: Post-Earnings, Still a Buy
-
China Biotech in Review: Cross Border Collaborations
-
3SBio Reports Higher Sales, Flat Earnings
-
China Biopharma Undergoes Systemic Changes
-
3SBIO Files for Approval on Three New Drugs
-
China Bio in Review: More Fallout from Economic Crisis
-
3SBio's Q3 Hurt by Lehman Bankruptcy
-
China Biotech in Review: Deals, Developments and Financials
-
3SBio Files for Approval of Anemia Treatment
-
China Biotech Week in Review: Earnings, Earnings, Earnings
-
3SBio Reports Higher Q2 Revenues but Earnings Slip
-
Six Key Chinese Healthcare ADRs
-
China ADRs: Mixed July
-
China Stocks: Top Ten by PEG
-
China Biomedical Industry Evolving
-
China ADRs: Severe Loss in June
-
Is 3SBio Too Conservative to Move Forward?
-
China ADRs: Mixed May
-
China Biotech Week in Review: Earnings, Deals and Drug Development
-
AMAG Pharma, 3SBio Partner to Develop Ferumoxytol Market in China
-
3SBio to Commercialize Iron Deficiency Agent in China
-
China Biopharma Growth Metrics
-
3SBio’s Q1: Revenues Rise, Net Income Lags
-
China Stocks: April Was Kind
-
China Stocks: Still No Sign of a Bottom
-
China Biotech in Review: Approvals, Deals and Company News
-
3SBio Finally Pleases Investors
-
Is 3SBio the Chinese Amgen?
-
New China Biopharma Investments
-
3SBio Drops on Missed Estimates
-
3SBio Plunges on Q4 Earnings Miss
-
China Biotech Week in Review: East-West Interdependence in 2007
-
China Biotech in Review: Effective Collaboration Between US-Asian Companies and US Investors
-
3SBio Bucks The Trend: Reports Impressive Earnings, Stock Jumps
-
3SBio Rises After Hours on Earnings
-
It's More than Just Baidu: 51 Other Ways to Invest in China
-
Recent Chinese IPOs Continue To Shine
-
Best, Worst Performing Chinese ADRs YTD